Country
Switzerland
The immune checkpoint inhibitor Tecentriq (atezolizumab) met its primary endpoint of disease-free survival in a Phase 3 study in people with early non-small cell lung cancer, Roche announced on 22 March.
Full text available to subscribers only. Click here for information on subscribing to MedNous.